Citations

Clear

5 citation(s) found for "Scout, N F N".

Intimate Demographic Questions: Are Patients With Cancer Comfortable Answering?
Suleiman, Riham , Looney, Sandy M., Fee-Schroeder, Kelliann C., Phelan, Lynn M., Carroll, Evelyn F. , Randall, Kristen, Bush, Blaz, Alpert, Ash B. , Scout, NFN , Jatoi, Aminah , Cathcart-Rake, Elizabeth J , Randall, Kristen, Cathcart-Rake, Elizabeth

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | April 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10499091261440518 | PMID 41947289 Get It

Purpose To assess how comfortable patients with cancer are in responding to intimate questions on sexual orientation and gender identity (SOGI) and to examine whether question sequencing alters patient-reported comfort. Patients and Methods Patients with cancer were asked to respond to one of two surveys that were provided to patients in a randomized manner and that included seven identical SOGI questions but differed in sequence of responses (upfront vs later debated terms, e.g. “genderqueer”). Using a Likert scale (1 = very uncomfortable to 5 = very comfortable), patients rated comfort. The primary endpoint was the percentage of patients comfortable with the question, “Do you consider yourself to be… [12 response options, including genderqueer]”. Secondary endpoints included differences in comfort based on question sequence or demographics. Write-in comments were captured. Results 74% of patients (95% CI: 70%, 78%) were comfortable when reviewing the primary endpoint SOGI question. Similar comfort levels were reported for the other questions. No significant differences in comfort were observed based on question sequence or demographics. Four themes emerged from write in comments 1) emotional reactions to the questions (“uncomfortable because this question is essentially gender binary”) 2) emotional reactions toward SOGI (“bending over backwards to be politically correct”); 3) concern for privacy and relevance to cancer care (“not sure why this information is needed/necessary”); and 4) constructive remarks (“didn’t know what cisgender was - please define”). Conclusions Most patients with cancer are comfortable in answering SOGI questions. However, their comfort might be enhanced with slight question/response modifications.
Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups
Cathcart-Rake, Elizabeth , Thao, Viengneesee , Le‐Rademacher, Jennifer , Helfinstine, David A. , Ruddy, Kathryn, Vachon, CM, Davidge-Pitts, Caroline, Carroll, Evelyn F. , Scout, N F N, Ridgeway, Jennifer L. , Shufelt, Chrisandra , Jatoi, Aminah , Scout, NFN , Cathcart-Rake, Elizabeth J , Ruddy, Kathryn J , Vachon, Celine M. , Carroll, Evelyn, Scout, Nfn , Shufelt, Chrisandra L , Tevaarwerk, Amye J , Jatoi, Aminah , Le-Rademacher, Jennifer G , Ridgeway, Jennifer L , Ruddy, Kathryn J. , Davidge‐Pitts, Caroline , Tevaarwerk, Amyé

Mayo Clinic

Journal of Clinical Oncology | March 3, 2026 | Volume: 44 | Issue: 11 | Pages: 981-991

10.1200/jco-25-01659 | PMID 41774876 Get It

PURPOSE This national study was undertaken to determine screening mammography rates among transgender and gender diverse (TGD) individuals. METHODS TGD individuals and cisgender women who qualified to receive screening mammography based on American College of Radiology guidelines were identified in the longitudinal OptumLabs Data Warehouse. The primary end point was the percentage of patients who had high rates of screening (>75% recommended screenings). Multivariable analyses were conducted in a matched population of transgender men to cisgender women to identify and adjust for factors associated with high adherence. Individuals were matched at a 1:4 ratio (transgender men: cisgender women) on age, race/ethnicity, year of enrollment in their health care plan, and duration of follow-up. RESULTS This study focused on 10,478 TGD individuals (3,778 transgender men; 1,294 transgender women; 5,406 with gender dysphoria not meeting other TGD criteria, NMOT) and 6,218,369 cisgender women. For transgender men, transgender women, individuals with gender dysphoria NMOT, and cisgender women, high mammography rates were observed in 41.1% (95% CI, 39.5 to 42.6), 7.4% (95% CI, 6.0 to 8.8), 11.9% (95% CI, 11.0 to 12.7), and 38.3% (95% CI, 38.3 to 38.4), respectively ( P < .0001). When transgender men were compared with 15,112 matched cisgender women, an age-based differential association was observed between sex and high mammography rates (interaction P = .0003); compared with cisgender women, transgender men appeared more likely to manifest high rates of screening at age 40-49 years (odds ratios [ORs], 1.38 [95% CI, 1.28 to 1.50]; P < .0001) and 50-59 years (OR, 1.57 [95% CI, 1.35 to 1.81]; P < .0001) but not in the older age groups. CONCLUSION The relatively high rates of screening mammography in cisgender women and transgender men suggest clinicians are offering mammography to individuals who are at average or high breast cancer risk, as compared with cisgender women, and not to transgender women at low risk.
Incidence of Acute Mountain Sickness in Adolescents Backpacking at Philmont Scout Ranch
Sharp, Courtney LL, Ditmars, Hayley , Stoltzfus, Ky, Filardi, Tanya , Hyde, Robert J., Mullan, Aidan F. , Hyde, Robert J.

Mayo Clinic

Wilderness & Environmental Medicine | September 9, 2024 | Volume: 35 | Issue: 4 | Pages: 403-408

10.1177/10806032241281230 | PMID 39248159 Get It

Introduction Individuals ascending to elevations above 2500 m are at risk of developing altitude illness. We sought to establish the incidence and to determine what risk factors, if any, increased the likelihood of developing acute mountain sickness (AMS) in adolescents at Philmont Scout Ranch (PSR) in Cimarron, New Mexico. PSR, with elevations ranging from 2011 to 3792 m, attracts thousands of adolescent participants each year, many of whom arrive from lower elevations with little or no experience ascending to high altitude. Methods We conducted a prospective observational study of adolescent participants aged 14 to 19 years who ascended to a minimum of 3000 m while trekking from June to July 2021. Prior to the start of each participant's trek, pretrek survey data were obtained at PSR's basecamp (2011 m). During the trek at 3048 m, the Lake Louise AMS score was used to diagnose AMS. Results The incidence of AMS in our study was 13.7%. Participants reporting a history of daily headaches had more than four times the risk of developing AMS. A history of gastrointestinal problems carried three times the risk of developing AMS, and a prior history of AMS increased the risk of developing AMS by 44%. Conclusions Our findings enhance our understanding of AMS risk in adolescents and may provide guidance to youth for developing AMS. For individuals with a history of headaches or gastrointestinal problems or a prior history of AMS, there may be an opportunity to reduce the risk of developing AMS.
175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)
Walter, Emmanuel B. , Newland, Jason G. , Lee, Howard , Hofto, Meghan E. , Oler, Randolph E., Conrad, Thomas, Tuyishimire, Bonifride, Fowler, Vance G. , Chambers, Henry F. , Zaoutis, Theoklis E., Williams, Derek J. , Creech, C. Buddy , Martin, Judith M. , Gerber, Jeffrey S. , Staat, Mary Allen , Pettigrew, Melinda M. , Fowler, Vance G. , Evans, Scott , Huskins, W. Charles

Mayo Clinic

Open Forum Infectious Diseases | January 2, 2021 | Volume: 7 | Issue: Supplement_1 | Pages: S216-S216

10.1093/ofid/ofaa439.485 Get It

Abstract Background Community-acquired pneumonia (CAP) in children is usually treated with 10 days of antibiotics. Shorter antibiotic courses may be beneficial if proven effective, with potentially fewer antibiotic adverse effects and decreased antibiotic exposure. Methods This randomized, double-blind, placebo-controlled superiority trial (NCT02891915) compared a strategy of short vs standard course ß-lactam therapy for outpatient CAP in children ages 6–71 months. Children demonstrating clinical improvement by day 3–5 of initial therapy were considered for enrollment. Enrolled children were randomized 1:1 to receive either 5 additional days of the originally prescribed antibiotic (standard) or matching placebo (short). The Desirability of Outcome Ranking (DOOR; PMID: 26113652) was the primary outcome, and was defined by classifying the global experience of children into an ordinal clinical response (OCR) that combined the response to CAP treatment and antibiotic adverse effects 11–15 days after the start of therapy. For those subjects with equivalent OCR, documented days of antibiotic administration was used to further rank the desirability of the outcome with the a priori assumption that shorter antibiotic exposure was more desirable. The OCR was a secondary outcome. The intention to treat population was used to estimate the probability of a more desirable outcome for the strategy of short vs. standard course therapy for both outcomes. Results 385 children were enrolled; 380 had complete data for analysis. Baseline characteristics were similar between the two strategies. In both strategies, &gt; 90% of children had an adequate response to CAP treatment and most antibiotic adverse effects were minor (Table). In the OCR analysis, short course therapy had a 48% probability (95% CI: 42%-53%) of a more desirable outcome. In the DOOR analysis, short course therapy was superior to standard therapy with a 69% probability (95% CI: 63%-72%; p&lt; 0.001) of a more desirable outcome. Conclusion Among children with CAP demonstrating initial clinical improvement with outpatient therapy, both strategies had a similar response to CAP treatment and antibiotic adverse effects, but short course therapy was superior in our a priori defined outcome that incorporated decreased antibiotic exposure. Disclosures Emmanuel B. Walter, MD, MPH, Moderna (Grant/Research Support)Pfizer (Grant/Research Support) Jason Newland, MD, MEd, FPIDS, Merck (Grant/Research Support)Pfizer (Other Financial or Material Support, Industry funded clinical trial) Vance G. Fowler, Jr., MD, MHS, Achaogen (Consultant)Actavis (Grant/Research Support)Advanced Liquid Logics (Grant/Research Support)Affinergy (Consultant, Research Grant or Support)Affinium (Consultant)Allergan (Grant/Research Support)Ampliphi Biosciences (Consultant)Basilea (Consultant, Research Grant or Support)Bayer (Consultant)C3J (Consultant)Cerexa (Consultant, Research Grant or Support)Contrafect (Consultant, Research Grant or Support)Cubist (Grant/Research Support)Debiopharm (Consultant)Destiny (Consultant)Durata (Consultant)Forest (Grant/Research Support)Genentech (Consultant, Research Grant or Support)Integrated Biotherapeutics (Consultant)Janssen (Consultant, Research Grant or Support)Karius (Grant/Research Support)Locus (Grant/Research Support)Medical Biosurfaces (Grant/Research Support)Medicines Co. (Consultant)Medimmune (Consultant, Research Grant or Support)Merck (Consultant, Research Grant or Support)NIH (Grant/Research Support)Novadigm (Consultant)Novartis (Consultant, Research Grant or Support)Pfizer (Grant/Research Support)Regeneron (Consultant, Research Grant or Support)Tetraphase (Consultant)Theravance (Consultant, Research Grant or Support)Trius (Consultant)xBiotech (Consultant) W. Charles Huskins, MD, MSc, ADMA Biologics (Consultant)Pfizer, Inc (Consultant)
Dose Modification for Safe Treatment of a Compound Complex Heterozygous DPYD Variant Carrier With Fluorouracil
Shrestha, Shikshya , Tapper, Erin E. , Trogstad-Isaacson, Colbren S., Hobday, Timothy J. , Offer, Steven M. , Diasio, Robert B. , Trogstad-Isaacson, Colbren Scout, Offer, Steven M

Mayo Clinic

JCO Precision Oncology | October 3, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-5

10.1200/po.18.00179 | PMID 32039342 Get It